Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC decreased its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 21.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 128,078 shares of the biopharmaceutical company's stock after selling 34,648 shares during the period. Exchange Traded Concepts LLC owned about 0.10% of Dynavax Technologies worth $1,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVAX. Russell Investments Group Ltd. increased its stake in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 1,169 shares during the period. Smartleaf Asset Management LLC increased its stake in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 2,034 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Dynavax Technologies in the fourth quarter worth $35,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Dynavax Technologies in the fourth quarter worth $71,000. Finally, GAMMA Investing LLC grew its position in shares of Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after buying an additional 3,627 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. JMP Securities dropped their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, Dynavax Technologies currently has a consensus rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Stock Down 3.0%

DVAX stock traded down $0.31 during trading on Friday, reaching $9.99. 5,233,685 shares of the company traded hands, compared to its average volume of 2,176,187. Dynavax Technologies Corporation has a 12 month low of $9.22 and a 12 month high of $14.63. The business has a 50 day simple moving average of $10.30 and a 200 day simple moving average of $12.06. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -19.21 and a beta of 1.06. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.84 and a current ratio of 11.93.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. The company had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. On average, equities research analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.